Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nyse  >  Merck and Company    MRK

MERCK AND COMPANY (MRK)
Mes dernières consult.
Most popular
  Report  
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsofficial PublicationsSector newsTweets
OFFRE ETE Zonebourse : Jusqu'à 6 mois offerts sur tous les portefeuilles

Merck Hepatitis C Drug Shows Promise in Study; Abbott Updates Data

share with twitter share with LinkedIn share with facebook
share via e-mail
0
11/10/2012 | 03:15pm CEST
   By Peter Loftus 
 

A regimen containing an experimental Merck & Co. (>> Merck & Co., Inc.) drug suppressed the hepatitis C virus in most patients in a new clinical trial, and appears to be more potent than the company's Victrelis treatment.

The mid-stage study included the injectable drug interferon that Merck and its rivals hope to drop from future regimens. Merck now plans to conduct new studies of its drug, MK-5172, as part of a potential all-oral hepatitis C regimen that eliminates interferon, which can be difficult for patients to tolerate.

Merck is among a pack of drug companies--including Gilead Sciences Inc. (>> Gilead Sciences, Inc.) and Abbott Laboratories (>> Abbott Laboratories)--racing to tap what's expected to be a multibillion-dollar market for all-oral regimens. Current standard therapies, including Merck's Victrelis, are typically given with interferon.

Hepatitis C is a viral disease that attacks the liver, and is believed to afflict about 180 million people world-wide, with more than four million in the U.S., according to the National Institute of Allergy and Infectious Diseases. At-risk groups include people who had blood transfusions before 1992, when a screening test for the virus was developed.

Merck is presenting clinical data for MK-5172 at the annual meeting of the American Association for the Study of Liver Diseases in Boston, which began Friday.

MK-5172 is a so-called protease inhibitor, the same class of drug as Victrelis, which went on sale last year and generated $387 million in sales for the first nine months of 2012. But MK-5172 is designed to be more potent and to carry a higher barrier to treatment resistance than Victrelis, said Eliav Barr, vice president of infectious diseases with Merck's research arm.

In a phase 2, or mid-stage, clinical trial of about 330 patients with hepatitis C, patients were given various dose levels of MK-5172 in combination with the drugs ribavirin and interferon for 12 weeks. One group of patients received Victrelis plus ribavirin and interferon--which is now a standard treatment.

The study found that 96% of patients who received the 100-milligram dose of MK-5172 had sustained virologic response 12 weeks after treatment ended, the highest response rate of the various treatment groups. Sustained virologic response is roughly equivalent to being virus-free or having nearly undetectable viral levels.

By comparison, some 54% of patients in the Victrelis group achieved sustained virologic response at 12 weeks. This is lower than what prior, larger studies have shown for Victrelis. In prior studies, the drug led to sustained virologic response in about two-thirds of patients at 24 weeks after treatment.

Higher doses of MK-5172 were associated with liver toxicities, said Dr. Barr.

Because the study contained interferon, additional studies are needed to test whether MK-5172 is efficacious without interferon.

Merck plans to conduct phase 2 studies of MK-5172 in combination with another experimental oral drug, MK-8742, plus ribavirin, which is also an oral drug. If testing goes well, Merck may consider removing ribavirin from the regimen and pursuing a combination of MK-5172 and MK-8742, he said. Ideally, they could be combined in a once-daily tablet.

"We're looking for something highly efficacious, short duration, well-tolerated and all-oral," he said.

Dr. Barr declined to provide a timeline for when Merck might be in a position to submit a new hepatitis C regimen for regulatory approval.

Analysts generally view Gilead as leading the all-oral hepatitis C race, with Abbott Labs and Bristol-Myers Squibb Co. (>> Bristol Myers Squibb Co.) also still in the hunt. Bristol experienced a setback this summer when one of its hepatitis C compounds failed because of safety issues, but it has others in the pipeline. These companies are expected to present additional, updated data on their drugs at the AASLD meeting.

Abbott Labs reported some results for its hepatitis C drugs in October. Updated results show that a combination of three experimental Abbott drugs--ABT-450 combined with the boosting agent ritonavir, ABT-267 and ABT-333--plus ribavirin led to 12-week sustained virologic response rates of 97% in patients who hadn't received prior treatment, and 93% in patients who had received prior treatment.

In addition, a group of patients who received the Abbott drugs without ribavirin had a sustained virologic response rate of 87% at 12 weeks. These patients hadn't received prior treatment.

"We think the efficacy is a very exciting result to see," said Barry Bernstein, head of hepatitis C development at Abbott.

About 1% of patients discontinued study treatment due to adverse events, Abbott said.

Abbott has begun phase 3, or late-stage testing, of its hepatitis C regimen, with and without ribavirin. The company expects it may secure regulatory approval for a regimen by early 2015 if further testing is positive.

Write to Peter Loftus at [email protected]

Subscribe to WSJ: http://online.wsj.com?mod=djnwires

Stocks mentioned in the article
ChangeLast1st jan.
ABBOTT LABORATORIES 0.31% 61.94 Delayed Quote.8.53%
BRISTOL-MYERS SQUIBB COMPANY 2.22% 55.14 Delayed Quote.-11.98%
GILEAD SCIENCES -0.63% 71.07 Delayed Quote.-0.80%
MERCK AND COMPANY 0.47% 61.47 Delayed Quote.9.24%
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on MERCK AND COMPANY
06/23MERCK : Presents New Data from the Comparative Trials with Sitagliptin (CompoSIT..
BU
06/22MERCK AND : FDA restricts Keytruda, Tecentriq monotherapy
AQ
06/21AGILENT TECHNOLOGIES : Companion Diagnostic Gains Expanded FDA Approval in Cervi..
AQ
06/21MERCK AND : - Late-Breaking Data to be presented from the Comparative Trials wit..
AQ
06/21MERCK AND : CEO Kenneth Frazier, speaking in Philly, urges people to call out 'u..
AQ
06/20Latecomer Sanofi looks to catch next wave of cancer therapies
RE
06/18MERCK AND : Late-Breaking Data to be Presented from the Comparative Trials with ..
PU
06/18BRISTOL MYERS SQUIBB : BMS scores China's first IO approval
AQ
06/15MERCK AND : Modern Alchemists Are Making Chemistry Greener
AQ
06/15MERCK AND : `s Keytruda snags I-O`s first cervical cancer nod to back up HPV fig..
AQ
More news
News from SeekingAlpha
06/23What Does Breakthrough Therapy Designation Really Mean For My Company? 
06/21Key events next week - healthcare 
06/21Neon Therapeutics Firms Its Plan For $100 Million IPO 
06/19ALZHEIMER'S DISEASE : A History Of Drug Failures 
06/173 THINGS IN BIOTECH, JUNE 16 : Do You Know Anything About EHA? 
Financials ($)
Sales 2018 42 072 M
EBIT 2018 13 566 M
Net income 2018 7 224 M
Debt 2018 15 754 M
Yield 2018 3,17%
P/E ratio 2018 23,66
P/E ratio 2019 15,99
EV / Sales 2018 4,31x
EV / Sales 2019 4,10x
Capitalization 165 B
Chart MERCK AND COMPANY
Duration : Period :
Merck and Company Technical Analysis Chart | MRK | US58933Y1055 | 4-Traders
Technical analysis trends MERCK AND COMPANY
Short TermMid-TermLong Term
TrendsBullishBullishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 20
Average target price 69,1 $
Spread / Average Target 12%
EPS Revisions
Managers
NameTitle
Kenneth C. Frazier Chairman, President & Chief Executive Officer
Robert M. Davis CFO & Executive Vice President-Global Services
Thomas Henry Glocer Independent Director
Rochelle B. Lazarus Independent Director
Leslie A. Brun Lead Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
MERCK AND COMPANY9.24%165 373
JOHNSON & JOHNSON-12.08%329 475
PFIZER0.22%213 568
NOVARTIS-9.42%191 991
ROCHE HOLDING LTD.-10.81%191 785
AMGEN6.47%122 515